Form 4: Viking Therapeutics Director Sells Shares Under 10b5-1 Trading Plan

J. Matthew Singleton, a director at Viking Therapeutics, sold 5,700 shares of common stock at an average price of $69.7246, while also exercising options to acquire 5,700 shares at $1.19, all under a pre-arranged trading plan.

Summary

• On August 21, 2024, J. Matthew Singleton, a director of Viking Therapeutics, Inc., engaged in transactions involving the company's common stock.
• Singleton exercised stock options to acquire 5,700 shares at a price of $1.19 per share.
• Concurrently, Singleton sold 5,700 shares of common stock at a weighted average price of $69.7246 per share, with individual sales prices ranging from $69.50 to $69.98.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on May 16, 2024.
• Following these transactions, Singleton directly owns 9,500 shares of Viking Therapeutics common stock and holds options for 10,300 shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it reports routine transactions under a pre-arranged trading plan. There is no indication of positive or negative implications for the company.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. The use of a 10b5-1 trading plan indicates that the transactions were pre-planned and not based on any material non-public information.

Key Dates